03038500

# UNITED STATES

SECTION 4(6), AND/OR UNIFORM LIMITED OFFERING EXEMPT

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549


FORM D NOTICE OF SALE OF SECURITIES PURSUANT TO REGULATION D,

OMB APPROVAL OMB Number: 3235-0076

May 31, 2005

Expires: Estimated average burden

hours per response......16.00



Name of Offering: [ ] (check if this is an amendment and	name has changed, and	ndicate change.)	1	n 12.18
TRIAD PHARMACEUTICALS, INC. Series E Preferred	Stock and underlying Co	mmon Stock.	$l \propto$	110300
Filing Under (Check box(es) that apply):	)4	□ Rule 506     □	Section 4(6)	ULOE
Type of Filing: New Filing Amend	lment			
	. BASIC IDENTIFICA	TION DATA		
1. Enter the information requested about the issuer.				
Name of Issuer: (check if this is an amendment and na	me has changed, and ind	icate change.)		
TRIAD PHARMACEUTICALS, INC.				
Address of Executive Offices	(Number and Street,	City, State, Zip Code)	Telephone Numbe	r (Including Area Code)
71 Warwick Road, Melrose, MA 02176			(781) 665-3118	_
Address of Principal Business Operations	(Number and Street,	City, State, Zip Code)	Telephone Numbe	r (Including Area Code)
(if different from Executive Offices)				DOCESSED
				DDOCESSER
Brief Description of Business The design and discovery	of pharmaceuticals.			4 2003
Type of Business Organization:				MON 14 5003
corporation limited partnership	, already formed	other (please specif	fy):	TION ISON
business trust limited partnership	, to be formed			FINANCIAL
	Month	Year		,,,,
Actual or Estimated Date of Incorporation or Organization	: 0 2	9 9	Actual	☐ Estimated
Jurisdiction of Incorporation or Organization: (Enter two-	letter U.S. Postage Servi	ce abbreviation for State	. D E	

## **GENERAL INSTRUCTIONS**

Who Must File: All issuers making an offering of securities in reliance on an exemption under Regulation D or Section 4(6), 17 CFR 230.501 et seq. or 15 U.S.C. 77d(6).

CN for Canada; FN for other foreign jurisdiction)

When To File: A notice must be filed no later than 15 days after the first sale of securities in the offering. A notice is deemed filed with the U.S. Securities and Exchange Commission (SEC) on the earlier of the date it is received by the SEC at the address given below or, if received at that address after the date on which it is due, on the date it was mailed by United States registered or certified mail to that address.

Where to File: U.S. Securities and Exchange Commission, 450 Fifth Street, N.W., Washington, D.C. 20549.

Copies Required: Five (5) copies of this notice must be filed with the SEC, one of which must be manually signed. Any copies not manually signed must be photocopies of the manually signed copy or bear typed or printed signatures.

Information Required: A new filing must contain all information requested. Amendments need only report the name of the issuer and offering, any changes thereto, the information requested in Part C, and any material changes from the information previously supplied in Parts A and B. Part E and the Appendix need not be filed with the SEC.

Filing Fee: There is no federal filing fee.

This notice shall be used to indicate reliance on the Uniform Limited Offering Exemption (ULOE) for sales of securities in those states that have adopted ULOE and that have adopted this form. Issuers relying on ULOE must file a separate notice with the Securities Administrator in each state where sales are to be, or have been made. If a state requires the payment of a fee as a precondition to the claim for the exemption, a fee in the proper amount shall accompany this form. This notice shall be filed in the appropriate states in accordance with state law. The Appendix to the notice constitutes a part of this notice and must be completed.

### **ATTENTION**

Failure to file notice in the appropriate states will not result in a loss of the federal exemption. Conversely, failure to file the appropriate federal notice will not result in a loss of an available state exemption unless such exemption is predicated on the filing of a federal notice.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number

A. BASIC IDENTIFICATION DATA
2. Enter the information requested for the following:
<ul> <li>Each promoter of the issuer, if the issuer has been organized within the past five years;</li> </ul>
• Each beneficial owner having the power to vote or dispose, or direct the vote or disposition of, 10% or more of a class of equity securities of the fissuer;
• Each executive officer and director of corporate issuers and of corporate general and managing partners of partnership issuers; and
Each general and managing partner of partnership issuers.
Check Box(es) that Apply:
Full Name (Last name first, if individual)
Bachovchin, William
Business or Residence Address (Number and Street, City, State, Zip Code)
71 Warwick Road, Melrose, MA, 02176
Check Box(es) that Apply:
Full Name (Last name first, if individual)
Kiritsy, Christopher
Business or Residence Address (Number and Street, City, State, Zip Code)  1001 Brickell Bay Drive, 25 <sup>th</sup> Floor, Miami, FL, 33131
Check Box(es) that Apply:   Promoter Beneficial Owner Executive Officer Director General and/or Managing Partner
Full Name (Last name first, if individual)
Parker, Lynne
Business or Residence Address (Number and Street, City, State, Zip Code)
27 West 24th Street, Suite 402, New York, NY, 10019
Check Box(es) that Apply:
Full Name (Last name first, if individual) Sudmeier, James
Business or Residence Address (Number and Street, City, State, Zip Code) 71 Warwick Road, Melrose, MA, 02176
Check Box(es) that Apply:    Promoter   Beneficial Owner   Executive Officer   Director   General and/or Managing Partner
Full Name (Last name first, if individual) Jaharis, Michael
Business or Residence Address (Number and Street, City, State, Zip Code) 475 Park Avenue South, New York, NY, 10016
Check Box(es) that Apply:
Full Name (Last name first, if individual) Stone Life Sciences Holdings, Ltd.
Business or Residence Address (Number and Street, City, State, Zip Code)
635 S. Orange Ave., Suite 10, Sarasota, Florida, 34236  Check Box(es) that Apply:
Check Box(es) that Apply: Promoter Beneficial Owner Executive Officer Director General and/or Managing Partner  Full Name (Last name first, if individual)
· · · · · · · · · · · · · · · · · · ·
Business or Residence Address (Number and Street, City, State, Zip Code)
Check Box(es) that Apply:
Full Name (Last name first, if individual)
Business or Residence Address (Number and Street, City, State, Zip Code)
Check Box(es) that Apply:
Full Name (Last name first, if individual)
Business or Residence Address (Number and Street, City, State, Zip Code)

(Use blank sheet, or copy and use additional copies of this sheet, as necessary)

B. INFORMATION ABOUT OFFERING	
	Yes No
1. Has the issuer sold, or does the issuer intend to sell, to non-accredited investors in this offering?	
Answer also in Appendix, Column 2, if filing under ULOE.  2. What is the minimum investment that will be accepted from any individual?	¢ 31/4
2. What is the minimum investment that will be accepted from any individual?	\$ <u>N/A</u> Yes No
3. Does the offering permit joint ownership of a single unit?	Yes No □
4. Enter the information requested for each person who has been or will be paid or given, directly or indirectly, any commission or	
similar remuneration for solicitation of purchasers in connection with sales of securities in the offering. If a person to be listed is an	
associated person or agent of a broker or dealer registered with the SEC and/or with a state or states, list the name of the broker or	
dealer. If more than five (5) persons to be listed are associated persons of such a broker or dealer, you may set forth the information for that broker or dealer only.	
Full Name (Last name first, if individual)	
Business or Residence Address (Number and Street, City, State, Zip Code)	
Name of Associated Broker or Dealer	
States in Which Person Listed Has Solicited or Intends to Solicit Purchasers	
(Check "All States" or check individual States)	All States
[AL] [AK] [AZ] [AR] [CA] [CO] [CT] [DE] [DC] [FL] [GA] [HI] [ID] [IL] [IN] [IA] [KS] [KY] [LA] [ME] [MD] [MA] [MI] [MN] [MS] [MO]	
[MT] [NE] [NV] [NH] [NJ] [NM] [NY] [NC] [ND] [OH] [OK] [OR] [PA]	
[RI] [SC] [SD] [TN] [TX] [UT] [VT] [VA] [WA] [WV] [WI] [WY] [PR]	
Full Name (Last name first, if individual)	
Business or Residence Address (Number and Street, City, State, Zip Code)	
Name of Associated Broker or Dealer	
Traine of Associated Biorei of Bearei	
States in Which Person Listed Has Solicited or Intends to Solicit Purchasers	
(Check "All States" or check individual States)	All States
[AL] [AK] [AZ] [AR] [CA] [CO] [CT] [DE] [DC] [FL] [GA] [HI] [ID]	
[IL] [IN] [IA] [KS] [KY] [LA] [ME] [MD] [MA] [MI] [MN] [MS] [MO] [MT] [NE] [NV] [NH] [NJ] [NM] [NY] [NC] [ND] [OH] [OK] [OR] [PA]	
[RI] [SC] [SD] [TN] [TX] [UT] [VT] [VA] [WA] [WV] [WI] [WY] [PR]	
Full Name (Last name first, if individual)	
Business or Residence Address (Number and Street, City, State, Zip Code)	
Name of Associated Broker or Dealer	
States in Which Person Listed Has Solicited or Intends to Solicit Purchasers	
(Check "All States" or check individual States)	
[AL] [AK] [AZ] [AR] [CA] [CO] [CT] [DE] [DC] [FL] [GA] [HI] [ID]	[] All States
[IL] [IN] [IA] [KS] [KY] [LA] [ME] [MD] [MA] [MI] [MN] [MS] [MO]	
[MT] [NE] [NV] [NH] [NJ] [NM] [NY] [NC] [ND] [OH] [OK] [PA]	
[RI] [SC] [SD] [TN] [TX] [UT] [VT] [VA] [WA] [WV] [WI] [WY] [PR]	
Full Name (Last name first, if individual)	
Business or Residence Address (Number and Street, City, State, Zip Code)	
Name of Associated Broker or Dealer	
States in Which Person Listed Has Solicited or Intends to Solicit Purchasers	□ <b>411</b> 04 /
(Check "All States" or check individual States)	All States
[AL] [AK] [AZ] [AR] [CA] [CO] [CT] [DE] [DC] [FL] [GA] [HI] [ID] [IL] [IN] [IA] [KS] [KY] [LA] [ME] [MD] [MA] [MI] [MN] [MS] [MO]	
[MT] [NE] [NV] [NH] [NJ] [NM] [NY] [NC] [ND] [OH] [OK] [OR] [PA]	
[RI] [SC] [SD] [TN] [TX] [UT] [VT] [VA] [WA] [WV] [WI] [WY] [PR]	

(Use blank sheet, or copy and use additional copies of this sheet, as necessary.)

1.	Enter the aggregate offering price of securities included in this offering and the total amount already sold. Enter "0" if answer is "none" or "zero." If the transaction is an exchange offering, check this box and indicate, in the columns below the amounts of the securities offered for exchange and already exchanged.			
	Type of Security		Aggregate fering Price	Amount Already Sold
	Debt	\$	0	\$0
	Equity	\$	1,000,000	\$ 1,000,000
	☐ Common ☑ Preferred			,
	Convertible Securities (including warrants)	\$	0	\$ 0
	Partnership Interests	\$	0	\$ 0
	Other (Specify)	\$	0	\$ 0
	Total	\$	1,000,000	\$ 1,000,000
	Answer also in Appendix, Column 3, if filing under ULOE.			
2.	Enter the number of accredited and non-accredited investors who have purchased securities in this offering and the aggregate dollar amounts of their purchases. For offerings under Rule 504, indicate the number of persons who have purchased securities and the aggregate dollar amount of their purchases on the total lines. Enter "0" if answer is "none" or "zero."			Aggregate
			Number Investors	Aggregate Dollar Amount of Purchases
	Accredited Investors		1	\$ 1,000,000
	Non-accredited Investors		0	<u>\$</u> 0
	Total (for filings under Rule 504 only)	wannyay -		\$
	Answer also in Appendix, Column 4, if filing under ULOE.			
3.	If this filing is for an offering under Rule 504 or 505, enter the information requested for all securities sold by the issuer, to date, in offerings of the types indicated, in the twelve (12) months prior to the first sale of securities in this offering. Classify securities by type listed in Part C - Question 1.		Type of	Dollar Amount
	Type of offering		Security	Sold
	Rule 505		·	\$
	Regulation A			\$
	Rule 504			\$
	Total			\$
4.	a. Furnish a statement of all expenses in connection with the issuance and distribution of the securities in this offering. Exclude amounts relating solely to organization expenses of the issuer. The information may be given as subject to future contingencies. If the amount of an expenditure is not known, furnish an estimate and check the box to the left of the estimate.			
	Transfer Agent's Fees			\$
	Printing and Engraving Costs			\$
	Legal Fees			\$7,500
	Accounting Fees			\$
	Engineering Fees			\$
	Sales Commissions (specify finders' fees separately)			\$
	Other Expenses (identify)			\$
	Total		🖾	\$7,500
	b. Enter the difference between the aggregate offering price given in response to Part C - Question	n 1 and to	tal	
	b. Enter the difference between the aggregate offering price given in response to Part C - Question expenses furnished in response to Part C - Question 4.a. This difference is the "adjusted gross the issuer."	n 1 and to proceeds	tal to	\$992,500

5.	for each of the purposes shown. If the a and check the box to the left of the estim	ed gross proceeds to the issuer used or proposed to be under the mount for any purpose is not known, furnish an estimate late. The total of the payments listed must equal the forth in response to Part C - Question 4.b above.		
			Payments to Officer Directors, and Affiliates	s, Payments to Others
	Salaries and fees		S	<u> </u>
	Purchase of real estate		<u> </u>	<u> </u>
	Purchase, rental or leasing and insta	allation of machinery and equipment	\$	. \$
	Construction or leasing of plant bui	ldings and facilities	<u> </u>	. 🗆 🖫
	offering that may be used in exchar	cluding the value of securities involved in this age for the assets or securities of another issuer	□ <u>\$</u>	<u> </u>
	Repayment of indebtedness		□ <u>\$</u>	. \$
	Working capital		□ <u>\$</u>	<b>№</b> \$992,500
	Other (specify):			
	•			\$992,500
Total Payments Listed (column totals added)			🛭 🖾 <u>\$99</u>	22,500
		D. FEDERAL SIGNATURE	and the second second	
sig	nature constitutes an undertaking by the is	igned by the undersigned duly authorized person. If this suer to furnish to the U.S. Securities and Exchange Cor n-accredited investor pursuant to paragraph (b)(2) of R	is notice if filed under Rule 5 nmission, upon written requ	
Iss	uer (Print or Type)	Signature 1 0 0	Date	
TR	IAD PHARMACEUTICALS, INC.	William W. Sachowhen	November 10, 20	03
Na	me of Signer (Print or Type)	Title of Signer (Print or Type)		
	lliam Bachovchin	President		

## **ATTENTION**

Intentional misstatements or omissions of fact constitute federal criminal violations. (See 18 U.S.C. 1001.)